Vertex Pharmaceuticals, Inc.

Some of the best links we picked up around the internet

CRISPR Therapy Moves Into Younger Children

Jun. 24, 2026

The first approved CRISPR medicine has now shown similarly strong results in children as young as five years old with sickle cell disease and...

CMN Weekly (13 February 2026) - Your Weekly CRISPR...

CMN Weekly

Feb. 13, 2026

Some of the best links we picked up around the internet

CMN Weekly (12 December 2025) - Your Weekly CRISPR...

CMN Weekly

Dec. 12, 2025

Some of the best links we picked up around the internet

CMN Weekly (19 September 2025) - Your Weekly...

CMN Weekly

Sep. 19, 2025

Some of the best links we picked up around the internet

CMN Weekly (15 August 2025) - Your Weekly CRISPR...

CMN Weekly

Aug. 15, 2025

Some of the best links we picked up around the internet

CMN Weekly (8 August 2025) - Your Weekly CRISPR...

CMN Weekly

Aug. 8, 2025

Some of the best links we picked up around the internet

CMN Weekly (13 June 2025) - Your Weekly CRISPR...

CMN Weekly

Jun. 13, 2025

Some of the best links we picked up around the internet

Vertex Pharmaceuticals, Inc.

Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05477563)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Sickle cell disease, SCD, (NCT05951205)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT04208529)
Sponsors:
Vertex Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III

Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05356195)
Sponsors:
Vertex Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT05329649)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (2018-001320-19)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT03655678)
Sponsors:
Vertex Pharmaceuticals Inc.

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT03745287)
Sponsors:
Vertex Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III